Three drugs selected for DIAN TU clinical trial

Scientists at the Dominantly Inherited Alzheimer’s Network Trials Unit (DIAN TU) have selected three drugs to be evaluated in the first phase of this innovative international clinical trial. The drugs each target beta amyloid — the main ingredient in the brain plaques found in people with Alzheimer’s — in a different way. The Alzheimer’s Association provided $4.2 million in funding for DIAN to build the essential infrastructure for its Trials Unit.
Read the article >>

http://news.wustl.edu/news/Pages/24400.aspx

http://www.optimumseniorcare.com/services/alzheimerscare.php